Delving into the Latest Updates on Meloxicam with Synapse

Overview

Basic Info

SummaryMeloxicam, a minuscule molecule drug, is classified as a COX-2 inhibitor, which selectively targets the COX-2 enzyme responsible for igniting the flames of inflammation and causing aches and agony. Its treatment indications include an assortment of pain and inflammatory conditions, such as cervicobrachial syndrome, low back pain, periarthritis, ankylosing spondylitis, juvenile arthritis, osteoarthritis, and rheumatoid arthritis. Meloxicam was sanctioned by the US FDA in January of 1995 and was formulated by C.H. Boehringer Sohn AG & Co. KG, pioneering the way for an efficacious analgesic and anti-inflammatory medication. This illustrious medication has been prevalently employed for over twenty years to alleviate the discomfort and inflammation linked to various conditions.

Drug Type

Small molecule drug

Synonyms

Meloxicam (JAN/USP/INN), Meloxicam-CPL-05, 美洛昔康-CPL-05

+ [29]

Target

COX-1 x COX-2

Action

inhibitors

Mechanism

COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

Pain, PostoperativeModerate painSevere pain+ [9]

Inactive Indication

Abdominal PainAcute pharyngitisAnkylosing Spondylitis+ [6]

Originator Organization

Cali (Shenzhen) Biosciences Co. Ltd.C.H. Boehringer Sohn AG & Co. KG

Active Organization

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.Nippon Boehringer Ingelheim Co., Ltd.Avondale Pharmaceuticals LLC

+ [11]

Inactive Organization

Baudax Bio, Inc.

Iroko Pharmaceuticals LLCBoehringer Ingelheim Pharmaceuticals, Inc.

+ [4]

License Organization

RXILIENT HEALTH PTE LTD

Zyla Life Sciences LLC

Nanjing Qingpu Biotechnology Co., Ltd.

+ [3]

Drug Highest PhaseApproved

First Approval Date

Finland (27 Feb 1996)

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC14H13N3O4S2

InChIKeyZRVUJXDFFKFLMG-UHFFFAOYSA-N

CAS Registry71125-38-7

The hollow fiber membrane (HFM) system is a potential combined dissolution/permeation in vitro tool to predict oral solid dosage form performance. However, drug permeability interpretation in the presence of surfactants remains mechanistically challenging, particularly when surfactants are present in both the donor and receiver compartments. A model denoted the reduced resistance model was recently employed to explain enhanced drug permeability when surfactant was present in the receiver. The objective was to re-examine previously published HFM flux of griseofulvin and meloxicam to consider the reduced resistance model as an additional contributing mechanism impacting drug flux. Published HFM data under all four surfactant experimental scenarios (i.e., no surfactant, surfactant in the receiver only, surfactant in the donor only, and surfactant in both donor and receiver) were re-analyzed. For the latter two most complex scenarios, there were six competing permeation models. For these two scenarios, the best predictive model for griseofulvin was the reduced resistance model for total donor drug concentration; meanwhile, for meloxicam, which was much less micelle incorporated, the best predictive model was the simple free drug permeation model. Overall, these findings demonstrate that drug permeation across HFM in surfactant-containing systems is governed by the interplay between donor-side micellar sequestration and receiver-side resistance reduction.

01 Jul 2026·JOURNAL OF ARTHROPLASTY

Intravenous Meloxicam Versus Ketorolac for Pain Control Following Total Joint Arthroplasty: A Double-Blind Randomized Controlled Trial

Article

Author: Osman, Brian M ; Moore, Maya R ; Samineni, Aneesh V ; Hernandez, Victor H ; Rizzo, Michael G ; Constantinescu, David S ; Shittu, Aziz T ; D'Apuzzo, Michele R ; Tabibi, Orel ; Fiala, Robert S ; Costello, Joseph P

BACKGROUND:

Although joint arthroplasty surgery is considered safe and effective in reducing osteoarthritis-related pain long-term, the surgery is known to be painful in the immediate postoperative period. Therefore, optimal pain management has become a crucial goal for orthopedic surgeons. Nonsteroidal anti-inflammatory drugs are often used but can cause adverse effects due to their mechanism of action. Meloxicam, however, has a unique mechanism of action, allowing it to better spare the gut lining, translating to reduced complications. This double-blind randomized controlled trial sought to compare intravenous (IV) meloxicam and IV ketorolac for total joint arthroplasty regarding pain scores, opioid consumption, and lengths of stay.

METHODS:

All other institutional protocols and medications remained unchanged. A total of 223 patients were randomized. The meloxicam group received 30 mg IV meloxicam preoperatively two hours before primary incision, while the ketorolac group received 15 mg IV ketorolac intraoperatively followed by 15 mg IV every six hours, scheduled for two doses. Pain, opioid consumption, and nausea were recorded at two and 24 hours postoperatively. An a priori power analysis demonstrated a need for 170 total patients. The study was registered on clinicaltrials.gov (NCT05291598) and received Institutional Review Board approval.

RESULTS:

The IV meloxicam group had increased total opioid consumption 24 hours postoperatively and longer lengths of stay than the IV ketorolac group; however, there were no differences in pain scores or nausea.

CONCLUSIONS:

The use of IV meloxicam as part of a perioperative pain management protocol led to increased opioid consumption, longer lengths of stay, and a lower rate of same-day discharges than IV ketorolac.

01 Jul 2026·JOURNAL OF ARTHROPLASTY

Reply to Letter Regarding “Is It Safe to Give Meloxicam or Celecoxib to Chronically Anticoagulated Patients Following Primary Total Knee Arthroplasty?”

Letter

Author: Liu, Jiabin ; Lee, Gwo-Chin

150

News (Medical) associated with Meloxicam

04 Jun 2026

·www.biospace.com

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO ® data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL. Details of the presentations are as follows: Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Richard Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine, NY Poster Number: T19 Title: Comparative Efficacy of SYMBRAVO vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Stephanis Nahas, MD, MSEd, Professor of Neurology, Thomas Jefferson University, PA Poster Number: T24 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Chia-Chun Chiang, MD, Assistant Professor of Neurology at the Mayo Clinic, Rochester, MN Poster Number: T30 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Fred Cohen, MD, Assistance Clinical Professor of Neurology, Icahn School of Medicine, Mount Sinai, NY Poster Number: T33 About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X . Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI ® , AUVELITY ® , and SYMBRAVO ® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614 adong@axsome.com Media: Darren Opland Senior Director, Corporate Communications (929) 837-1065 dopland@axsome.com

Phase 3NDA

04 Jun 2026

·axsometherapeuticsinc.gcs-web.com

Axsome Therapeutics Presents New SYMBRAVO® Data at the American Headache Society (AHS) 68th Annual Scientific Meeting

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO® data at the American Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL. Details of the presentations are as follows: Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Richard Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine, NY Poster Number: T19 Title: Comparative Efficacy of SYMBRAVO vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Stephanis Nahas, MD, MSEd, Professor of Neurology, Thomas Jefferson University, PA Poster Number: T24 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Chia-Chun Chiang, MD, Assistant Professor of Neurology at the Mayo Clinic, Rochester, MN Poster Number: T30 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Fred Cohen, MD, Assistance Clinical Professor of Neurology, Icahn School of Medicine, Mount Sinai, NY Poster Number: T33 About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614 adong@axsome.com Media: Darren Opland Senior Director, Corporate Communications (929) 837-1065 dopland@axsome.com

Phase 3NDA

19 May 2026

·allsci.com

FDA accepts Viatris’s NDA for MR-107A-02 fast-acting meloxicam for acute pain

Viatris (Nasdaq: VTRS) has submitted a New Drug Application (NDA) to the US FDA for MR-107A-02 (fast-acting meloxicam), an investigational oral reformulation of the NSAID meloxicam, seeking approval for the treatment of moderate-to-severe acute pain in adults. The FDA has accepted the application for review and assigned a PDUFA goal date of December 27, 2026. The NDA was filed under the 505(b)(2) regulatory pathway, which permits applicants to rely in part on existing safety and efficacy data for a previously approved compound. In this case, meloxicam is a well-characterized NSAID; the novelty of MR-107A-02 lies in its formulation, which Viatris says was engineered to accelerate dissolution and absorption relative to currently marketed oral meloxicam products. The company has not disclosed a proposed brand name. No priority review designation was mentioned in the company’s announcement. Clinical evidence supporting the application The NDA is supported by data from two randomized, double-blind, placebo-controlled Phase III trials conducted in post-surgical acute pain models. The herniorrhaphy trial (NCT06215859) enrolled 579 subjects, and the bunionectomy trial (NCT06215820) enrolled 410 subjects. Both studies included an active comparator arm using tramadol 50 mg every six hours to confirm pain model sensitivity, alongside placebo and MR-107A-02 arms. The primary endpoint in both trials was the Sum of Pain Intensity Difference over 0–48 hours (SPID 0–48h), measured using the Numeric Rating Scale. Viatris reported that MR-107A-02 met the primary endpoint in both studies. In the herniorrhaphy trial, the least-squares mean difference in SPID 0–48h versus placebo was 50.1 (95% CI: 35.4–64.8; p<0.001). In the bunionectomy trial, the corresponding figure was 82.7 (95% CI: 62.0–103.4; p<0.001). Secondary endpoints included opioid rescue medication use; the company said 72.6% of MR-107A-02-treated patients in the herniorrhaphy study were opioid-free versus 58.6% in the placebo arm (p=0.002), and 56.9% versus 33.1% in the bunionectomy study (p<0.001). Viatris said adverse events were consistent with the established NSAID class profile. Top-line results were presented at PAINWeek 2025. Scientific and competitive context The NDA enters a space that has seen renewed activity following the January 2025 US FDA approval of Journavx (suzetrigine), developed by Vertex Pharmaceuticals (Nasdaq: VRTX, Cambridge, Massachusetts). Suzetrigine is a selective NaV1.8 sodium channel inhibitor — a first-in-class mechanism that blocks peripheral pain signal transmission without central nervous system activity or opioid receptor engagement. Its approval was the first for a new non-opioid mechanism in acute pain in over two decades. MR-107A-02 operates through a different and more familiar mechanism. Meloxicam is a COX-2-preferential NSAID that inhibits prostaglandin synthesis; the compound’s anti-inflammatory and analgesic properties are well understood from years of use in chronic pain indications. The formulation strategy behind MR-107A-02 addresses a recognized pharmacokinetic limitation of conventional oral meloxicam, which reaches peak plasma concentration approximately five to six hours after dosing — too slow for acute pain management. Accelerating absorption is the central clinical rationale for the reformulation. The two assets are therefore mechanistically distinct and may occupy different positions in clinical practice. Suzetrigine represents a novel target with no addiction liability and no NSAID-class toxicity concerns, but carries drug-drug interaction constraints and limited real-world data one year post-launch. MR-107A-02, if approved, would bring an established safety and tolerability profile with the added benefit of faster onset, potentially offering a familiar option for prescribers already comfortable with the NSAID class. Acute pain affects more than 80 million people in the US annually, according to figures cited by Viatris, and opioids remain a frequently used treatment escalation despite well-documented harms. More than half of surgical patients report inadequate pain relief under current regimens, according to the company’s filing background. The regulatory and clinical impetus to expand non-opioid options for moderate-to-severe pain is well established, and the FDA’s acceptance of the MR-107A-02 application adds to a growing field of non-opioid analgesic development targeting this gap. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.

100 Deals associated with Meloxicam

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00969	Meloxicam	M01AC06	DB00814

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	China	Nanjing Qingpu Biotechnology Co., Ltd.	30 Apr 2025
Moderate pain	United States	Nanjing Qingpu Biotechnology Co., Ltd.	22 Apr 2025
Severe pain	United States	Nanjing Qingpu Biotechnology Co., Ltd.	22 Apr 2025
Juvenile Idiopathic Arthritis	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	11 Aug 2005
Juvenile Idiopathic Arthritis	United States	Avondale Pharmaceuticals LLC	11 Aug 2005
Cervicobrachial syndrome	Japan	Nippon Boehringer Ingelheim Co., Ltd.	10 Sep 2004
Low Back Pain	Japan	Nippon Boehringer Ingelheim Co., Ltd.	10 Sep 2004
Periarthritis	Japan	Nippon Boehringer Ingelheim Co., Ltd.	10 Sep 2004
Rheumatoid Arthritis	Australia	Boehringer Ingelheim Pty Ltd.	23 Feb 2001
Osteoarthritis	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	13 Apr 2000
Pain	China	-	01 Jan 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthralgia	Phase 3	United States	Iroko Pharmaceuticals LLC	01 Feb 2013
Osteoarthritis, Knee	Phase 3	China	Boehringer Ingelheim GmbH	01 Jul 2004
Ankylosing Spondylitis	Phase 3	-	Boehringer Ingelheim GmbH	01 Jul 2001
Systemic onset juvenile chronic arthritis	Phase 3	Austria	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	Belgium	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	France	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	Germany	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	Italy	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	Russia	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	United Kingdom	Boehringer Ingelheim GmbH	01 Sep 2000

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06306131 (CTgov)	Phase 2	Obesity	4	calcium carbonate 750 milligram (Placebo)	wplcergqsl(vfpoktabmw) = pwwhlvcqaq yqexwmhzdy (gfcalomvnz, 1.53) View more	-	30 Jun 2026
				Levonorgestrel 1.5 milligram+Meloxicam 15 milligram (Levonorgestrel Plus Meloxicam)	wplcergqsl(vfpoktabmw) = larpoulirj yqexwmhzdy (gfcalomvnz, 0) View more
NCT05695352 (OVULATION, CTgov)	Phase 2	-	19	Placebo (Placebo Comparator in Normal Ovulatory Women)	nbzileojfv(slaoqopryz) = auqoijjuqu nyytemprvf (gambiiwpvm, 2.24) View more	-	17 Jun 2026
				Levonorgestrel+meloxicam (Active Intervention in Normal Ovulatory Women)	nbzileojfv(slaoqopryz) = rblebptcvk nyytemprvf (gambiiwpvm, 2.7) View more
NCT04115098 (Pubmed \| Rheumatology (Oxford))	Phase 2	Axial Spondyloarthritis	30	celecoxib	hkwilpvxcy(tkyespryzu) = phnmmryekj bympzmsubl (ezexooowsl )	Positive	01 Dec 2025
				naproxen	hkwilpvxcy(tkyespryzu) = vbmdkcysth bympzmsubl (ezexooowsl )
ACR2025	Not Applicable	Axial Spondyloarthritis	30	Celecoxib	nktngrchka(sajipnwphg) = Adverse events were infrequent and mild across all NSAIDs, with only one serious adverse event (diarrhea) reported. ovcumpbirs (axvcxieoof ) View more	Positive	24 Oct 2025
				Meloxicam
NCT06215820 (Company_Website) Manual	Phase 3	Acute Pain	410	MR-107A-02 (bunionectomy subjects)	nexieytdzx(ledojrpcft): Difference (LS Mean) = 82.7 (95% CI, 62.0 - 103.4), P-Value = <0.001 View more	Positive	08 May 2025
				Placebo (bunionectomy subjects)
NCT06215859 (Company_Website) Manual	Phase 3	Acute Pain	579	MR-107A-02 (herniorrhaphy subjects)	jyozzalszy(bxgntunmkp): Difference (LS Mean) = 50.1 (95% CI, 35.4 - 64.8), P-Value = < 0.001 View more	Positive	08 May 2025
				Placebo (herniorrhaphy subjects)
NCT05974501 (CTgov)	Phase 4	complications of arthroplasty \| Osteoarthritis, Knee \| Pain, Postoperative	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	hfmsdtrfkn(chxknrzjjm) = tvbwksnxcx nvsgxjjxjf (zlnvtxbpga, vnseigsxxm - xxwdptpgcr) View more	-	12 Feb 2025
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	hfmsdtrfkn(chxknrzjjm) = legazkoyfn nvsgxjjxjf (zlnvtxbpga, yuflbmoqlx - hjjpcdmvry) View more
CTR20222580 (Pubmed)	-	Pain, Postoperative	132	美洛昔康-QP001	eqtbjtriuf(wnpiongser) = gnrrnoqxsd pujebagbwh (rmtjgybwky )	Positive	01 Oct 2024
				安慰剂	eqtbjtriuf(wnpiongser) = uhwqaugfyq pujebagbwh (rmtjgybwky )
NCT05291598 (CTgov)	Phase 3	Pain	223	Ketorolac (Ketorolac Group)	lmexdsyzpc(jqmmyuwuhv) = wxnjpapoeb lbcifwzgnn (cgthppuyss, 3.25) View more	-	14 Aug 2024
				IV meloxicam (IV Meloxicam Group)	lmexdsyzpc(jqmmyuwuhv) = slkfqxxwct lbcifwzgnn (cgthppuyss, 3.39) View more
NCT05315479 (CTgov)	Phase 4	Pain, Postoperative	19	N1539	wtddnlvzxy = naroklfhel aurrdbeaxt (pwlhpzfgvl, kvxmvbuvnp - ensfqwllpb) View more	-	13 Sep 2023